Biotech VC Funds

Medevice Capital is a Paris-based venture capital firm founded in 2011 that specializes in investing in early-stage MedTech and e-health startups. The fund primarily targets innovative companies in the healthcare sector, with a focus on medical devices and diagnostic technologies. Medevice typically invests in rounds ranging from $1 million to $5 million, supporting startups at the seed and later stages​. Some notable portfolio companies include Pixyl, which develops AI-driven medical imaging solutions, and Emagina, focused on women's health with a connected device for perineum care. Medevice also invested in Dyameo, which is working on cancer detection devices​. The firm is led by Cécile Réal, the founder and CEO, and its team has a strong background in healthcare entrepreneurship and investment. Medevice remains active, making approximately two investments per year, particularly within the European market.

Media Ventures, founded by Dirk Ströer, is a Cologne-based venture capital firm focusing on media, technology, telecommunications, and e-commerce sectors. Established in 2000, the firm has been instrumental in supporting innovative business models and emerging companies, primarily within Germany and Europe. Media Ventures seeks to empower entrepreneurs by providing both strategic investment and operational support, leveraging its deep-rooted expertise in media and advertising. The firm’s investment strategy revolves around backing early-stage to growth-stage companies that demonstrate potential for scalability and market leadership. Over the years, Media Ventures has built a diverse portfolio, including companies like aha.de, a longstanding player in the newsletter segment, and multiple digital marketing platforms. By maintaining a strong focus on digital and tech-based business models, the firm aligns its investments with the evolving media landscape, such as programmatic advertising, e-commerce solutions, and new media technologies. Dirk Ströer’s leadership has ensured that Media Ventures operates with a keen understanding of the industry's needs, often facilitating synergies between portfolio companies and his larger media empire, Ströer Group. This strategic integration helps startups scale faster by gaining access to comprehensive marketing solutions and broader distribution channels. Media Ventures continues to play a critical role in Germany’s media and tech ecosystem, fostering innovation and driving growth across digital and telecommunications markets.

Medicxi is a premier European venture capital firm specializing in life sciences, with a focus on drug discovery and therapeutic development. Established in 2016 by the former life sciences team of Index Ventures, the firm has raised over €1 billion across various funds. Medicxi’s flagship funds, such as Medicxi III (€400 million), invest in both early and late-stage biopharma companies. Notable investments include Genmab, Micromet (acquired by Amgen), and Minerva Neurosciences. Medicxi's investment strategy is centered around its "asset-centric" approach, where the firm invests in companies with strong clinical proof-of-concept that address clear unmet medical needs. Their investments typically range between €10 million and €25 million, supporting companies through key phases like clinical development and regulatory approval​. The firm partners closely with major pharmaceutical players such as Novartis, Johnson & Johnson, and GlaxoSmithKline, which provides strategic backing for its portfolio companies​. Headquartered in London, Geneva, and Jersey, Medicxi has become a leading name in European biotech, with a strong emphasis on translating scientific innovation into commercially viable drugs. Their portfolio spans across the full healthcare continuum, from early discovery to late-stage clinical assets, giving them a unique position in Europe’s life sciences ecosystem. Through its deep ties to industry leaders and a robust scientific advisory board, Medicxi continues to drive the next generation of breakthrough therapeutics​.

MedImmune Ventures was the wholly-owned corporate venture capital arm of AstraZeneca, founded in 2002 and headquartered in Gaithersburg, Maryland. The fund managed $400 million in an evergreen structure following AstraZeneca's commitment of an additional $100 million in November 2011. Senior Managing Director Ron Laufer led a team of three partners. Since 2009, the fund operated as a true evergreen vehicle, recycling proceeds from liquidated investments into new portfolio companies rather than returning capital to LPs on a fixed timeline. MedImmune Ventures focused on equity investments in private companies developing small and large molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging, and healthcare IT related to pharmaceutical product discovery and commercialization. Therapeutic areas covered infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system conditions, and gastrointestinal disease. The fund leads rounds. Across approximately 65 investments, the portfolio produced 4 IPOs and 11 acquisitions. Notable holdings include G1 Therapeutics (MedImmune led a $12.5 million Series A in October 2013 and the company later completed a $105 million Nasdaq IPO), Melinta Therapeutics, Astria Therapeutics, and Xencor. The fund also co-led a financing round in NeuProtect Pty Ltd, an Australian cardioprotectant company, alongside Starfish Ventures. MedImmune Ventures is now permanently closed and liquidated. During its active years, the fund served a dual mandate: generating financial returns for AstraZeneca while sourcing strategic intelligence about emerging biotech platforms across areas aligned with the parent company's therapeutic priorities. The evergreen structure allowed for patient capital deployment matched to the long development timelines of biopharmaceutical companies.

Medison Ventures is the corporate venture capital arm of Medison Pharma, one of the world's largest commercial partners for innovative pharmaceutical companies with operations in Israel, Canada, and Eastern Europe. Founded in 2016 by Meir Jakobsohn and headquartered in Petah Tikva, Israel, the firm focuses on in-licensing, equity investments, and scouting for breakthrough technologies in biotechnology and digital health. Investment activity is concentrated at the Series B stage in life sciences companies. The portfolio comprises approximately 10 investments across biotech, pharma, and digital health. Notable holdings include Alpha Tau Medical, an alpha particle cancer therapy company that completed a NASDAQ IPO in March 2021, along with Keros Therapeutics, Eloxx Pharmaceuticals, Apeiron Biologics, Allogene Therapeutics, Orchard Therapeutics, and ArQule. In 2019, Medison Ventures partnered with Pontifax to launch a $150 million venture debt fund providing clinical-stage life science companies with non-dilutive capital. Portfolio companies benefit from direct access to Medison Pharma's global network of pharmaceutical partners including Biogen, Vertex, Shire, BioMarin, IPSEN, Servier, PTC Therapeutics, and Daiichi-Sankyo. The fund's primary value proposition is commercial access: portfolio companies gain introductions to established pharmaceutical distributors and commercial partners through Medison Pharma's existing relationships, potentially accelerating the path from clinical development to market. The fund is currently presumed inactive with no publicly recorded recent investments, reflecting the typical life cycle of a focused corporate VC vehicle tied to its parent's strategic priorities.

Manifold Ventures (MMV) is a venture capital firm focused on supporting early-stage companies in healthcare innovation. Founded by physicians and healthcare entrepreneurs, MMV invests in startups that are developing groundbreaking medical technologies and solutions. The firm is known for its hands-on approach, offering more than just capital; they provide strategic guidance, operational expertise, and access to an extensive network of industry professionals. Their portfolio includes companies like Stellation (patient-provider matching technology), PocketRN (telehealth nursing), and Gradient Health (a healthcare data marketplace). MMV's team, led by Dr. Branden Rosenhan and Dr. Saumitra Thakur, brings deep experience in both clinical practice and business, which they leverage to help their portfolio companies navigate the complexities of the healthcare industry. MMV is headquartered in Salt Lake City and focuses on identifying promising healthcare innovations early in their development cycle, with the goal of helping these startups scale into successful enterprises.

MedVenture Partners, Inc., a Tokyo-based venture capital firm, specializes in early-stage investments within the life sciences sector, with a distinct focus on medical devices and healthcare technologies. Established in 2013 by Hajime Oshita and Dr. Fumiaki Ikeno, the firm has rapidly built a reputation for identifying and nurturing innovative startups poised to disrupt the healthcare landscape. Their portfolio includes standout companies such as Biomedical Solutions, Inc., which exemplifies their commitment to fostering groundbreaking technologies. MedVenture’s investment strategy is characterized by a hands-on approach, often leading funding rounds and providing substantial guidance to portfolio companies. They prioritize startups that demonstrate strong potential for global impact, particularly those addressing critical medical needs. Their geographic focus remains largely on Japan, but they have shown interest in companies that can expand internationally. With over 22 billion Yen in assets under management, MedVenture manages multiple funds, the most recent of which raised 99 billion Yen. The firm’s approach to investment is strategic and collaborative, leveraging deep medical expertise alongside innovative technology. Startups seeking investment should be prepared to present compelling, well-researched pitches that highlight their innovation and market potential. Led by a team of seasoned professionals, including Oshita, who has over two decades of experience in the medical device industry, MedVenture Partners is committed to driving successful exits and significant market advances. Their active involvement in the growth and development of their portfolio companies underscores their role as a key player in Japan’s venture capital landscape.

MEDX Ventures Group is a Hingham, Massachusetts-based investment and management company founded in 2010 by Harel, who serves as CEO and Company Group Chairman, with offices in the US, Europe, and Israel. The firm focuses on Israeli medical technology and robotic companies, applying a proprietary 'X Model' that provides active management through dedicated Development, Regulatory, Commercial, and Finance teams embedded alongside portfolio companies throughout their lifecycle. In 2015, MEDX raised $30 million for Israeli biomed startups and established MEDX Xelerator, a leading medical-device-focused incubator operating under the auspices of the Israel Innovation Authority. MEDX Xelerator is located in Or Yehuda and Sakhnin, Israel, and partners with Boston Scientific, Sheba Medical Center, Intellectual Ventures, Consensus Business Group, West Pharmaceuticals, Wolfson Hospital, Weill Cornell Medicine Enterprise Innovation, and Ichilov Hospital. Innovation areas include vascular, interventional cardiology, urology, interventional oncology, medical robotics, and digital health solutions. MEDX leads rounds and invests at pre-seed through Series A stages. Across approximately 8 investments, the portfolio includes Microbot Medical (IPO), XACT Robotics (Harel serves as Chairman), Append Medical ($7.4 million Series A), and VeinWay (most recent seed investment, March 2023). The related Edge Medical Ventures launched a $70 million medtech fund to complement MEDX's earlier-stage activity. The MEDX model differs from conventional medtech VCs in that its team actively manages regulatory strategy, commercial development, and financing alongside founders rather than providing capital and periodic board oversight. This hands-on operational approach is designed to reduce time-to-market and de-risk regulatory submissions for hardware-intensive medical devices and robotic surgical systems.

Menlo Ventures, a Silicon Valley-based venture capital firm, has a robust history of investing in transformative technology companies across consumer, enterprise, and healthcare sectors. Notable investments include Uber, Roku, Warby Parker, Poshmark, and Chime. The firm focuses on early-stage investments but supports companies through their entire growth journey. Menlo Ventures recently closed a $1.35 billion fund aimed at backing the next generation of AI startups, reflecting its commitment to cutting-edge technologies. The firm also emphasizes deep involvement with portfolio companies, offering strategic guidance and support through every stage of development.

Merantix is a Berlin-based AI venture studio that has been building and investing in AI-driven startups since 2016. It operates Europe's largest AI platform, focusing on ideating, incubating, and scaling AI ventures across various industries. The company is notable for its emphasis on transformative AI applications, particularly in B2B sectors. Merantix has recently launched a €100 million fund, which is divided into three parts: €25 million for co-investing in external startups, €25 million for incubating new ventures, and €50 million for supporting existing investments. This marks a significant expansion from its traditional model, where it primarily incubated its own startups with an initial €1 million investment in exchange for equity. The firm has incubated successful companies like Vara, an AI breast cancer detection startup, and Cambrium, which focuses on AI-powered protein design. Merantix also hosts the AI Campus in Berlin, a 5,200 sqm co-working and community space dedicated to AI innovation, bringing together startups, corporations, and investors to foster collaboration. Merantix’s investment strategy focuses on early-stage companies, particularly in pre-seed and Series A rounds, with a strong emphasis on supporting founders who have deep domain expertise and a passion for AI.

Mercia Asset Management is a leading UK-based specialist asset manager that focuses on providing capital across four core asset classes: venture capital, private equity, debt, and balance sheet investments. Established initially as a seed capital provider linked to universities, it has grown to manage over £1.4 billion in assets, emphasizing support for small and medium enterprises (SMEs) across the UK, especially in underserved regional markets. The firm’s investment approach is built around its "Complete Connected Capital" model, which combines funds under management (FuM) with direct investments from its balance sheet. This hybrid strategy allows Mercia to offer flexible, long-term capital to startups and scale-ups, typically investing up to £10 million per round. Mercia's extensive portfolio covers sectors such as technology, healthcare, and advanced manufacturing, with notable investments in companies like Oxford Genetics and Netacea. Mercia operates nine regional offices, helping it maintain a close connection with local businesses, and collaborates with government bodies, institutional investors, and private individuals. The firm’s effective management of EIS (Enterprise Investment Scheme) and VCT (Venture Capital Trust) funds has enabled it to deliver consistent returns, achieving an average premium of around 53% on exits. Since its IPO in 2014, Mercia has demonstrated a solid track record in supporting the growth of UK regional businesses while delivering dividends to its investors, underpinning its strategy to be the top regional capital provider in the UK.

Mercia Asset Management, based in the UK, is a leading provider of venture, private equity, and debt financing, with a strong regional focus outside London. With over £1.5 billion in assets under management, Mercia actively backs early-stage businesses in sectors like AI, digital health, clean tech, and biosciences. Notable investments include Netacea (cybersecurity) and Nova Pangaea (sustainable aviation fuel), reflecting its commitment to high-growth sectors. Mercia typically invests between £500k to £20m, supporting startups through multiple stages of growth, including Seed to Series B. The firm’s focus on regional UK businesses helps address funding gaps, with 77% of their recent investments outside London. Their strategy prioritizes long-term partnerships with founders, often maintaining investments for five to seven years. The team, led by CEO Dr. Mark Payton, has a track record of successful exits, including the £100m sale of Faradion and the sale of nDreams to Aonic. Mercia's portfolio also benefits from its affiliation with major initiatives like the Northern Powerhouse Investment Fund, which helps accelerate regional growth. Mercia is known for being approachable and hands-on, offering mentorship alongside capital​.

Meridian Street Capital is a venture capital firm established in 2016, based in New York City. The firm specializes in early-stage investments at the intersection of healthcare and technology. Their approach is to support founders from the earliest stages, often from day one, to help turn innovative ideas into category-defining companies. Meridian Street Capital has a strong portfolio that includes companies like 1upHealth, ClosedLoop.ai, and Jona Health, among others. They focus on investing in businesses that leverage technology to improve healthcare services, access, and efficiency. Typically, their investments range from $100K to $5M, with a sweet spot around $1.5M. The firm has a hands-on approach, providing strategic guidance and leveraging their industry connections to support the growth of their portfolio companies. The team at Meridian Street Capital includes key figures such as George Ribaroff and T. Scott Law Jr., who bring extensive experience in venture capital and healthcare technology. They have a focused strategy, partnering with a concentrated group of startups to ensure dedicated support and resources. Meridian Street Capital has made a total of 47 investments and has seen several successful exits, including Valify and Hint Health. Their investment strategy emphasizes backing exceptional teams with innovative solutions that have the potential to transform healthcare.

Meron Capital, founded in 2017 and based in Tel Aviv, is an early-stage venture capital firm focused on investing in deep-technology software startups. The firm, led by managing partners Liron Azrielant and Daniel Roditi, has raised two funds, Meron I and Meron II, each with $50 million. Meron Capital primarily invests in sectors such as enterprise software, cybersecurity, digital health, fintech, and DevOps, targeting pre-seed and seed-stage companies. Notable investments by Meron Capital include Loom Systems, acquired by ServiceNow; Reshuffle, acquired by Twitter; Clear Genetics, acquired by Invitae; and Axonize, acquired by Planon. The firm’s current portfolio also includes promising startups like LendAI, Sorbet, Firmbase, and Laminar​. Meron Capital prides itself on a founder-first approach, providing not just capital but also strategic guidance and leveraging their extensive network to help startups scale. They emphasize backing resilient and technically proficient founders who are capable of pushing through challenges and leveraging subtle expert feedback to refine their business models​.

Merus Capital, founded in 2008 and based in Palo Alto, California, focuses on early-stage investments, primarily from pre-seed to Series A rounds. The firm specializes in sectors such as HR tech, big data and analytics, artificial intelligence and machine learning, biotech, and developer tools. Merus Capital has made 104 investments and has had 30 successful exits, including notable companies like Amplitude, Iterable, and Symphony​. Other prominent portfolio companies include Emi Labs, Censia, Moesif, and Modern Health​. Co-founded by Sean Dempsey, Salman Ullah, and Peter Hsing, Merus Capital aims to support ambitious teams that are building industry-defining platforms. The firm offers substantial follow-on capital and leverages its extensive network to help portfolio companies scale effectively​.

Metaplanet Holdings, founded in 2011 by Jaan Tallinn, co-founder of Skype, is a venture capital firm based in Tallinn, Estonia. The firm focuses on early-stage investments in deep technology startups that promise long-term societal and civilizational impacts. Metaplanet emphasizes funding science-heavy projects and non-commercial research aimed at reducing existential risks, particularly from AI and other advanced technologies. Metaplanet has a diversified portfolio of over 150 startups, with notable investments including BillionToOne, a provider of cell-free cancer liquid biopsy tests, and Anthropic, an AI-based conversational chatbot service. The firm has made more than 50 successful exits, including companies like Ampler Bikes and Apprente. Recent investments include $7 million in the blockchain company Fhenix and $13 million in Neurable, a brain-computer interface technology company. The firm's investment strategy focuses on sectors such as AI, neuroscience, blockchain, and encryption, supporting innovations that have the potential to disrupt industries or create entirely new ones. Metaplanet's team, led by Managing Partner Rauno Miljand and Partner Alexey Morgunov, operates with a lean structure, enabling them to make impactful and strategic investments.

Metavallon VC, founded in 2018 and based in Athens, Greece, focuses on early-stage investments in technology startups, particularly those connected to Greece. They typically invest in seed and pre-seed stages, with initial funding tickets ranging from €500K to €1.5M. The firm emphasizes supporting startups in sectors like transportation and mobility, energy and cleantech, space and aviation, machine learning and AI, and more. Notable investments by Metavallon VC include Ferryhopper, a leading ferry booking platform, and Wikifarmer, which aims to democratize agricultural commerce. The firm has also successfully exited from companies such as Seervision, which specializes in AI-driven camera automation software, and Think Silicon, a provider of graphics technology solutions. Metavallon VC offers extensive support to their portfolio companies, including business development, B2B sales, recruiting, and exit planning. Their approach combines financial backing with hands-on guidance to help startups scale and achieve significant market impact. The leadership team includes George Karantonis, Myrto Papathanou, and Yorgos Mousmoulas, who bring extensive experience in venture capital and technology investments.

Metrodora Ventures is a New York-based venture capital firm founded in 2020 by Chelsea Clinton. The firm focuses on early-stage investments in the health and learning sectors, with a mission to support companies that improve access to care, education, and vital information. Metrodora Ventures is driven by a values-conscious approach, investing in purpose-driven startups that aim to make a significant impact on society. The firm’s portfolio includes innovative companies like Teal Health, which is developing telehealth platforms focused on women’s health, and Blooming Health, which creates technology to help older adults maintain connections with their communities. Another notable investment is Swing Therapeutics, which develops digital therapies for chronic illness management. Metrodora Ventures operates with the goal of nurturing its portfolio companies by providing capital, market insights, and industry relationships. The firm raised its debut fund of $20.8 million and is currently in the process of raising a second fund to continue its mission of fostering impactful startups.

Noshaq is an investment fund based in Liège, Belgium, that offers a range of financing solutions aimed at fostering the creation and growth of companies, particularly SMEs. Established in 1985 under the name Meusinvest, the organization has grown significantly and rebranded to Noshaq in 2019 to better reflect its innovative and dynamic approach to investment. Noshaq manages a portfolio of 477 companies and has supported over 1,020 companies since its inception. The fund's primary focus areas include biotechnology, industry 4.0, digital technology, quality food, real estate, energy, sustainable development, and cultural industries. They provide funding through various vehicles, including equity investments, loans, and leasing, tailored to the specific needs of each stage of a company's development. Notable initiatives under Noshaq include Noshaq Spin-Offs, which supports the creation of spin-offs in collaboration with the University of Liège, and LeanSquare, which focuses on innovative projects in cultural and creative industries, enterprise software, and life sciences. Additionally, Noshaq is actively involved in regional development projects, such as La Grand Poste, a creative hub in the heart of Liège.

MHS Capital, founded in 2006 and based in San Francisco, California, focuses on early-stage investments in technology-driven companies. They have a diverse portfolio, investing across sectors such as software, e-commerce, mobile, and healthcare. Notable investments include companies like Zenput, a business productivity software, and Grove Collaborative, an eco-friendly consumer goods company. MHS Capital has made a total of 102 investments, with 48 successful exits, including companies like Udemy and Thumbtack. The firm emphasizes close collaboration with visionary founders to build the next generation of category-defining companies.

mHUB, based in Chicago, is a leading innovation center for hardtech and manufacturing startups. Founded in 2017, mHUB has quickly established itself as a key player in driving innovation across various sectors, including climate tech, medtech, and smart manufacturing. Through its Product Impact Fund I, mHUB has invested in 46 startups, with a significant focus on sustainable manufacturing and clean energy technologies. Notable investments include Sensatek Propulsion Technology, Aeternal Upcycling, and Next-Ion, among others. mHUB’s strategic approach combines capital investment with robust support through its accelerator programs, providing startups with access to extensive prototyping labs, a vast network of industry mentors, and business leadership training. The mHUB community has generated over $1.89 billion in revenue, launched more than 1,600 products, and created over 5,500 jobs since its inception. The organization’s commitment to diversity is evident, with investments in underrepresented founders being 6.5 times higher than the national average. Key team members like Haven Allen, CEO and co-founder, and Melissa Lederer, Chief Experience Officer, play pivotal roles in steering the fund and supporting its portfolio companies towards commercialization and market success. Situated at the intersection of Chicago’s tech and manufacturing districts, mHUB leverages its location within an Opportunity Zone and Planned Manufacturing District to offer unique benefits to startups, such as eligibility for specific funding opportunities and federal contracts. With its new 80,000 square foot facility, mHUB continues to expand its capacity to support innovation and drive economic growth in the region.

Miami Angels, founded in 2013, is one of Florida's largest and most active angel networks. The group focuses on post-product, post-revenue, early-stage technology companies, and is industry agnostic. Their portfolio includes over 60 companies with more than $32 million invested. The organization works through its individual members, who make investments rather than the network itself. This allows for a diverse range of opportunities and perspectives within the tech startup ecosystem. Miami Angels supports various startups, including Caribu, Nearpod, and ClassTag, which span industries from educational technology to enterprise solutions​. Miami Angels values partnerships and collaborations, which help provide exceptional services and support to the companies in their network. Key partners include Kaufman Rossin, a leading accounting and advisory firm.

Middle East Venture Partners (MEVP) is one of the largest and most established venture capital firms in the Middle East, with a focus on investing in early and growth-stage technology startups across the GCC and Levant regions. Founded in 2010, MEVP manages over $300 million in assets and has invested in more than 60 startups, many of which operate in sectors such as fintech, e-commerce, mobility, SaaS, and healthtech. With offices in Dubai, Beirut, Bahrain, and Riyadh, MEVP targets innovative companies that have the potential to scale regionally and globally. Their portfolio includes successful companies like Anghami, the first legal music streaming platform in the Arab world to go public, Nana, a leading online grocery delivery service, and Bykea, a Pakistani super app offering transport and delivery services. MEVP offers both financial backing and strategic support to help these businesses grow, focusing on building sustainable, scalable models that align with local market needs. MEVP has also made significant exits, such as its partial exit from Fresha, a beauty and wellness platform, generating impressive returns. With its recent launch of the $150 million Middle East Venture Fund IV, MEVP continues to drive innovation by supporting digital services and tech-based solutions that address local challenges and tap into global trends​.

Middleland Capital, a venture capital firm founded in 2010 and based in Washington, D.C., focuses on innovative foodtech and agtech companies. With over $100 million invested and a portfolio of 25 direct investments, the firm supports high-growth companies that are looking to scale their de-risked technology and proven business models​. The firm's notable investments include AeroFarms, the largest indoor vertical farming company in the US; Soli Organic, a leading grower and marketer of fresh organic culinary herbs; and MycoTechnology, an ingredient company that utilizes proprietary processes to remove flavor defects in food products without chemicals or GMOs​​. Other significant investments include EarthOptics, which provides real-time soil data maps, and Farmwise, which develops systems to streamline farming operations and increase food production efficiency​. Middleland Capital has a strong track record of successful exits, such as Seventh Generation, which was acquired by Unilever, and Benson Hill, which went public on the NYSE. The firm continues to catalyze global change in food and health through its targeted investments in innovative technologies and sustainable solutions.

MIG AG, based in Munich, Germany, is a prominent venture capital firm investing primarily in deep tech and life sciences. Their notable portfolio includes BioNTech, renowned for its COVID-19 vaccine, and companies like German Bionic, developing exoskeletons, and iOmx Therapeutics, focusing on novel cancer treatments. With over €1.2 billion in committed capital, MIG AG targets early to mid-stage startups that drive technological advancements and societal benefits. Their strategy is to invest in companies with groundbreaking innovations in biopharmaceuticals, medical technology, digital health, advanced computing, and environmental tech. MIG AG is known for its rigorous due diligence and active involvement in portfolio companies, providing strategic support and leveraging an extensive network to foster growth. Key team members include co-founders Jürgen Kosch and Michael Motschmann, both based in Munich, who bring decades of experience in venture capital and entrepreneurship. Startups can approach MIG AG through direct contact or their extensive industry network, emphasizing innovative solutions with strong growth potential. For entrepreneurs seeking investment, MIG AG values clear, impactful pitches that demonstrate significant technological breakthroughs and market readiness.

Millennium Global Opportunities is a Luxembourg-based mixed-asset fund managed by Millennium FT. It offers investment opportunities to both mutual and institutional investors, with tailored fee structures for each group. The fund adopts an opportunistic investment strategy, actively managing a diverse portfolio that includes equities, currencies, interest rates, and futures. It also prioritizes risk management to capitalize on global trends while minimizing potential downsides. Since 2018, Millennium Global Opportunities has integrated environmental, social, and governance (ESG) factors into its investment decision-making process, reflecting a commitment to sustainability. The fund’s focus on sustainability aligns with the broader global shift towards responsible investing, as it aims to generate positive financial returns while considering the long-term environmental and social impacts of its investments. The fund currently manages over €25 million in assets and targets growth through investments in large-cap stocks, as well as sustainable assets. Key holdings in the fund's portfolio include Xetra-Gold, U.S. Treasury Notes, and other high-quality assets that offer both security and potential for appreciation. Millennium Global Opportunities has also earned recognition in the investment community, winning multiple Lipper Fund Awards for excellence in the Absolute Return category. Millennium FT's active management approach, combined with a strong focus on sustainability and risk mitigation, makes it a versatile investment vehicle for those looking to balance growth with responsibility. The fund is particularly well-suited for investors who are seeking to diversify their portfolios with a blend of traditional and sustainable assets.

Milltrust International Group is a specialist investment firm co-headquartered in London and Singapore, known for its focus on sustainable investment strategies. The firm manages assets across public and private markets, with a particular emphasis on addressing global challenges such as food security, climate change, and emerging economies. Their investment philosophy, termed "Sustainable Prosperity," integrates wealth creation with ethical, planet-friendly goals. Milltrust operates through several branches, including Milltrust Ventures, which focuses on venture capital investments in sectors like healthcare, technology, and sustainable agriculture. The firm also manages East West Private Wealth, a multi-family office dedicated to wealth management services that align with eco-conscious and transparent investment strategies. This diverse approach allows Milltrust to support both institutional investors and high-net-worth families globally. In recent years, Milltrust has invested in impactful projects such as sustainable agricultural land in Australia and New Zealand, and high-growth technology companies that promote environmental sustainability.

Mindset Ventures is an early-stage venture capital firm with a focus on B2B tech startups in sectors like fintech, cybersecurity, agriculture, healthcare, and enterprise software. The firm primarily invests in the U.S. and Israel, but its roots in Brazil make it a powerful gateway for companies expanding into Latin America. Mindset is known for its strategic support, offering portfolio companies access to key business development opportunities, especially in the Brazilian market. Notable investments include Turing, PayJoy, and Pecan, where the fund has been pivotal in helping these companies with international growth. Mindset's investment strategy combines agility with thorough due diligence, often co-investing alongside top-tier VCs. They generally target early-stage startups with tickets ranging from $1 million to $5 million and prefer companies with coachable founders open to strategic guidance. Co-founded by Daniel Ibri, who leads from São Paulo, the team is well-versed in international expansion, helping companies scale beyond their initial markets. For startups seeking funding, Mindset values transparency and expects a well-researched approach that highlights how founders plan to scale globally.

Mirae Asset Venture Investments is the venture capital arm of Mirae Asset Financial Group, a global financial services giant headquartered in South Korea. The venture fund focuses on early to growth-stage investments, particularly in the technology, life sciences, fintech, and consumer sectors. Their portfolio features prominent companies like Unacademy, Ola, Zomato, and Bigbasket, reflecting their strong interest in emerging markets and digital platforms. Geographically, the fund has a significant presence across Asia, particularly in India and Southeast Asia, as well as North America. Mirae Asset employs a long-term, research-driven investment strategy, often co-investing with other prominent VC firms like SIG Venture Capital and Peak XV Partners. They have been especially active in 2024, making several key investments across various sectors, including fintech startup Jupiter and online grocery platform HappyFresh. With a focus on strategic growth, they seek companies that can redefine industries or introduce innovative solutions, and provide not just capital but also robust portfolio management. Their team, led by key executives like Ashish Dave in India, supports portfolio companies with deep market insights and hands-on guidance​.

Miroma Ventures is the investment arm of The Miroma Group, focusing primarily on venture and growth-stage investments in consumer brands and media platforms. Based in London, the firm leverages the extensive marketing expertise and global network of The Miroma Group to accelerate the growth of its portfolio companies. This unique approach allows Miroma Ventures to offer a mix of capital investment and tailored marketing services, making them a strategic partner for companies looking to expand their reach and scale rapidly. Miroma Ventures typically invests in the Seed, Series A, and Series B stages, with investment sizes ranging from $250,000 to $5 million. The firm is known for its interest in sectors like food and beverage, beauty and personal care, e-commerce, and digital media. They also offer flexible financing solutions, such as media services in exchange for equity, combining both financial and marketing support. The company has backed over 50 brands globally, including well-known names like ClassPass and Pinterest, reflecting its strong track record in the consumer and media industries. Miroma Ventures is particularly interested in partnering with businesses that show strong growth potential and can leverage its marketing expertise to build long-term value. With its focus on purpose-driven investments and consumer engagement, Miroma Ventures continues to support innovative brands that connect with modern audiences while fostering substantial growth.

Mission Bay Capital is a venture capital firm based in San Francisco, focused on early-stage investments in the biosciences. Established in 2009, the firm aims to support innovative entrepreneurs addressing critical medical and environmental challenges. Their portfolio includes companies like Caribou Biosciences, Alector, Zymergen, and Mammoth Biosciences, which utilize cutting-edge technologies such as CRISPR for molecular diagnostics​​. The firm has recently raised its third fund, totaling $60 million, which will continue to invest broadly in biotechnology innovations. Mission Bay Capital operates MBC BioLabs, a life-science incubator that has helped launch 138 companies, raising over $3.5 billion in total. This incubator provides state-of-the-art equipment and services to early-stage biotech companies, enabling them to advance their research and development efficiently​. Mission Bay Capital is led by Douglas Crawford, Ph.D., along with a team of experienced professionals like Robert Blazej, Ph.D. They emphasize disciplined investing and a management culture rooted in respect and inclusion, aiming to deliver superior returns and strategic opportunities to their limited partners​.

Mission BioCapital, founded in 2009, is a venture capital firm that focuses on early-stage investments in life sciences companies. With offices in Cambridge, Massachusetts, and San Francisco, California, the firm supports startups from the idea phase through to key development milestones. Mission BioCapital emphasizes collaboration and innovation, providing capital and strategic support to help scientific solutions reach the clinic faster and more efficiently. The firm recently announced raising $275 million for its fifth fund, Mission BioCapital V, which is aimed at funding transformative startups in therapeutics, diagnostics, medical devices, laboratory tools, and drug delivery. This fund also emphasizes company creation, working with academic researchers and entrepreneurs to launch startups based on novel technologies. Notable portfolio companies include Caribou Biosciences, Effector Therapeutics, and Alector, with several successful exits and IPOs. Mission BioCapital has also co-founded companies like ARase Therapeutics, Arclight Therapeutics LLC, Jupiter Bioventures, and Telo Therapeutics, demonstrating its deep involvement in nurturing groundbreaking life science ventures. The team at Mission BioCapital includes experienced professionals like Dr. Michael D. Taylor, who has a significant background in drug development at Pfizer and startups like Deciphera Pharmaceuticals. Co-Managing Partner Steve Tregay also brings extensive experience from his tenure at FORMA Therapeutics and the Novartis Venture Fund.

Mistletoe, a venture capital firm based in Kanazawa, Japan, was founded by Taizo Son and Atsushi Taira in 2013. The fund focuses on early-stage investments in tech-driven startups with a strong emphasis on sustainability and social impact. Notable investments include Zipline, Playco, and Sea, reflecting their commitment to innovative and impactful ventures. Mistletoe's industry focus spans across biotechnology, clean energy, health tech, and entertainment, showing a diverse portfolio aimed at transformative technologies. Geographically, their investments are global, covering North America, Asia, and Europe, with recent activities in countries like Japan, the U.S., and Finland. Their strategy revolves around partnering with visionary founders who tackle global challenges. Mistletoe typically invests in seed to series A stages, often leading rounds with an average check size of around $2 million. They have a collaborative approach, frequently co-investing with firms like Sequoia Capital and Plug and Play Tech Center. Active in fostering an ecosystem of like-minded investors and entrepreneurs, Mistletoe values innovation and societal contributions highly. The team, including key members like Michael Kim and Satoshi Fujimura, is primarily based in Japan with a significant presence in Singapore. Startups looking to engage with Mistletoe should emphasize their mission-driven goals and innovative solutions. Approaching them through warm introductions and clear, impactful pitches increases the chances of successful engagement​.

Mithril Capital, founded in 2012 by Ajay Royan and Peter Thiel, is a venture capital firm based in Austin, Texas. The firm focuses on long-term investments across various sectors and geographies, partnering with teams that leverage technology to create lasting and valuable businesses. Mithril's investment philosophy emphasizes broadminded curiosity, capital discipline, and constructive skepticism, seeking to support industries that are ripe for technological disruption. Mithril's portfolio includes notable companies such as Helion Energy, which is pioneering fusion energy; Neocis, which is advancing robotics in dental surgery; and Glance, a rapidly growing consumer internet platform. Other significant investments include Nuvia (acquired by Qualcomm), Auris Health (acquired by Johnson & Johnson), and BlackSky, a leader in real-time geospatial intelligence. The firm prides itself on helping companies navigate critical growth inflection points, supporting them with strategic insights and substantial capital investments. This approach has enabled Mithril's portfolio companies to achieve remarkable advancements in their respective fields, from reshaping robotic surgery to revolutionizing decentralized finance and enhancing grid resilience with AI-driven energy storage solutions.

Mitsui & Co., a leading global trading and investment company, has a diverse portfolio across multiple industries. Founded in 1876 and headquartered in Tokyo, Mitsui has expanded its operations globally, focusing on sectors such as energy, healthcare, technology, and consumer goods. Notable investments by Mitsui & Co. include Lhyfe, a French company specializing in renewable green hydrogen production, aligning with Mitsui’s commitment to sustainable energy solutions. QurAlis, a biotechnology company, is developing precision medicines for ALS and other neurodegenerative diseases. Leash Biosciences is an AI-driven biotech firm revolutionizing medicinal chemistry. Kaltura, a leading video technology provider, went public through an IPO. Virident, a high-performance storage class memory solutions company, was acquired. Boston Biomedical focuses on novel cancer treatments. Proterra, a manufacturer of zero-emission vehicles, merged through a SPAC. Mitsui & Co. leverages its global network and industry expertise to support innovative companies and foster growth in various sectors.

Miyako Capital, established in 2013 and affiliated with Kyoto University, is a prominent venture capital firm based in Kyoto, Japan, with additional offices in Tokyo and Silicon Valley. The firm focuses on early-stage investments in deep-tech sectors such as biotechnology, artificial intelligence, robotics, healthcare, energy, and more. Notable investments by Miyako Capital include Sakana AI, Orange, and Viage Therapeutics. The firm has recently launched its third deep tech fund, Miyako Kyoto University Innovation No. 3 Investment Limited Partnership, aiming to raise JPY 20 billion (approximately USD 140 million) to support cutting-edge startups. This fund is part of their broader strategy to bolster deep tech innovation and facilitate global expansion for their portfolio companies​. Led by experienced venture capitalists like Yasuhiro Yamaguchi and Tsunesaburo Sugaya, Miyako Capital leverages its strong ties to academic institutions to identify and nurture groundbreaking technologies. The firm has a track record of backing research-driven startups, contributing significantly to Japan's deep tech landscape.

Mizuho Bank, a core subsidiary of Mizuho Financial Group, operates as a global financial services provider with an extensive network of over 505 branches in Japan and 38 other countries. Headquartered in Tokyo, Mizuho is a prominent player in both retail and corporate banking sectors. The bank’s name, meaning "golden ears of rice," signifies prosperity and growth. Mizuho Bank has a diverse investment portfolio and notable investments include a significant stake in Vietnam's leading digital payment company, M-Service, which showcases its focus on expanding digital financial services in emerging markets. The bank has also been involved in several high-profile M&A deals globally, leveraging its strong expertise in structured finance and equity underwriting. Mizuho's strategy emphasizes building long-term relationships with clients by offering tailored financial solutions that include equity and bond financing, M&A advisory services, and structured finance. The bank has also made substantial efforts to lead in sustainable finance, integrating ESG factors into its investment decisions and operations. Key members of Mizuho’s leadership, including CEO Koji Fujiwara, bring a wealth of experience and strategic vision, guiding the bank’s initiatives in innovative financial services and global expansion. For businesses seeking investment, Mizuho’s approach is to provide comprehensive support through its extensive global network and deep industry insights, making it a reliable partner for growth and sustainability​.

MMC Ventures is a London-based venture capital firm that has been supporting early-stage tech entrepreneurs for over 20 years. Focused on transformative technology, MMC specializes in sectors such as artificial intelligence (AI), data-driven health, fintech, and enterprise software. The firm has built a reputation for deep industry expertise, particularly in AI and data science, where it is one of Europe's most active investors. Notable investments include Synthesia, Signal AI, and Current Health, the latter of which was acquired by Best Buy. MMC’s investment strategy is research-led, with a dedicated team of specialists who help identify and develop cutting-edge technologies. They typically invest in Seed and Series A rounds, but a significant portion of their funds is reserved for follow-on rounds, ensuring long-term support for portfolio companies. MMC also places a strong emphasis on partnering closely with founders, providing more than just capital; they offer resources like MMC Connect, a platform that facilitates introductions, coaching, and talent acquisition. In recent years, MMC has expanded its portfolio across Europe, backing companies in markets from the UK to Eastern Europe. The firm is committed to building businesses with the potential to drive technological advancements and create a positive impact on society, as evidenced by its status as one of the first B Corporations in venture capital.

Mobile Internet Capital (MIC), established in 1999, is a venture capital firm based in Japan. The firm focuses on investing in innovative technology companies with a strong emphasis on internet and mobile-related sectors. MIC has a successful track record with 22 IPOs and numerous exits. Their portfolio includes companies like Gree, a social networking service provider, and Mercari, a popular marketplace app. MIC invests in early to growth-stage companies, supporting them through multiple rounds to help them achieve significant milestones and market expansion. MIC is known for its strategic approach, leveraging its deep industry knowledge and network to provide not only capital but also valuable guidance and connections to its portfolio companies. They aim to foster long-term growth and innovation in the tech industry.

Mohr Davidow Ventures (MDV) is one of Silicon Valley's longest-tenured early-stage venture capital firms, founded in 1983 by Larry Mohr and Bill Davidow — the latter a former senior vice president at Intel during the era when the 8086 architecture became the industry standard. Headquartered in San Mateo, California, MDV has built approximately USD 1.85 billion in cumulative assets under management across its fund history. The firm leads rounds and targets early-stage technology companies that redefine or create large new markets, partnering with entrepreneurs leveraging big data, applied analytics, and web and mobile cloud platforms in verticals from social commerce to finance, online marketing, consumer-driven healthcare, and clean-tech IT. Over four decades MDV has made roughly 404 investments and delivered a long list of IPOs and acquisitions. Notable portfolio companies include Brocade, Coupa (NASDAQ: COUP), Rambus, Shutterfly, Proofpoint, nLight, Rally Software, Rocket Fuel, Aryaka Networks, Verinata Health (acquired by Illumina), Ticketfly, HealthTap, Infusionsoft, and Genomatica. The managing team spans approximately eight people with six partners, including Managing Partner Jon Feiber and general partners Josh Green, Sue Siegel, Erik Straser, and Bill Ericson, each covering distinct sectors from cleantech to life sciences and hardware. MDV now primarily manages its legacy portfolio rather than actively deploying new capital, with its most recent disclosed investment being a round in HealthTap in August 2023. The firm's most recent portfolio exit was Analyte Health, acquired by Brightstar Capital Partners in August 2025. Over forty years the partnership has earned a reputation for backing category-defining companies and then staying engaged through the full arc from early revenue to exit.

Momenta is a leading venture capital firm specializing in Industrial Impact investments, focusing on digital innovators in sectors such as energy, manufacturing, smart spaces, and supply chain. They have a decade-long track record of scaling companies that drive significant industrial and environmental improvements. Notable portfolio companies include Tvarit, Fleet Space, FreeWire, and EquipmentShare, which reflect their emphasis on impactful, scalable technologies. Momenta's investment strategy involves early-stage funding and close collaboration with founders to foster business growth. They leverage a robust network of industrial partners and extensive industry experience to support their portfolio companies, offering more than just financial backing. Their approach includes strategic advice, connections to potential customers and partners, and assistance with market positioning and scaling operations. Geographically, Momenta operates across Europe and North America, with key team members based in cities like Seattle, Luzern, and San Francisco. The team includes experienced professionals like Michael Dolbec and Douglas Harp, who bring decades of expertise in digital transformation, industrial IoT, and strategic business development. Startups seeking investment should demonstrate innovative solutions with the potential for significant industrial impact. Momenta values strong leadership teams and scalable business models that align with their mission of driving digital transformation and sustainability in critical industries.

Monk's Hill Ventures, founded in 2014 by entrepreneurs Peng T. Ong and Kuo-Yi Lim, is a prominent venture capital firm based in Singapore. The firm focuses on early-stage investments, particularly pre-Series A and Series A, in Southeast Asia. Their portfolio includes over 50 high-growth tech companies across various sectors such as healthtech, fintech, edtech, e-commerce, and logistics. Some notable investments from Monk's Hill Ventures include Ninja Van, an app-based platform for last-mile delivery services; KKday, a platform for booking outdoor tours; and Glints, an online job board platform for graduates. Additionally, they have invested in companies like ELSA Speak, a mobile application for improving English speaking skills, and Waresix, an on-demand warehousing service provider. Monk's Hill Ventures supports its portfolio companies by providing not only capital but also entrepreneurial expertise and a strong network to help founders scale their businesses. They typically look for strong business fundamentals and sizable market opportunities in the companies they invest in, making only a select number of investments each year to ensure they can fully commit to their founders' success. The leadership team, including co-founders Peng T. Ong and Kuo-Yi Lim, brings extensive experience in building and investing in tech companies, reinforcing the firm's mission to empower Southeast Asia's most ambitious tech entrepreneurs.

Montage Ventures, headquartered in Menlo Park, California, is an early-stage venture capital firm that focuses on investments in the fintech, e-commerce, and healthcare sectors. The firm is renowned for backing innovative startups that challenge the status quo, including notable companies like MoneyLion, a digital bank aimed at the middle class, and PeerStreet, a tech-enabled real estate investment platform. Montage Ventures typically invests in the gap between Angel and Series A rounds, with an average investment size around $2M. They are involved in 7-12 deals per year, preferring to co-invest alongside other venture firms rather than leading rounds. The fund is particularly active in the United States, with significant investments in both the East and West Coasts. The firm’s strategy emphasizes supporting technical founders with deep industry knowledge and scalable solutions. Montage Ventures looks for startups with clear market demand and strong potential for growth. They prefer warm introductions and value detailed pitch decks that outline a clear business model and growth strategy. Startups looking to connect with Montage Ventures should demonstrate a robust product-market fit and innovative solutions within fintech, e-commerce, or healthcare. Their proactive and collaborative approach makes them a preferred partner for early-stage companies aiming for transformative impact.

Moonshots Capital is a seed-stage venture capital firm founded in 2017, with offices in Los Angeles and Austin. The firm focuses on investing in companies led by extraordinary leaders, particularly those who are military veterans or serial entrepreneurs. The co-founders, Kelly Perdew and Craig Cummings, leverage their extensive military and entrepreneurial experience to provide more than just capital to their portfolio companies, offering strategic guidance, operational support, and a vast network of contacts. Notable investments by Moonshots Capital include Slack, Robinhood, ID.me, and Bitium. The firm has a diverse portfolio that spans various sectors such as fintech, cybersecurity, consumer internet, and web3 technologies. Moonshots Capital takes an active role in the companies they invest in, often taking board seats or formal advisory roles to ensure they can provide maximum support and value. The firm's investment strategy prioritizes companies with strong leadership, a proven track record, and the potential for high growth. Moonshots Capital typically invests in companies that have a product with client traction, monthly recurring revenue of at least $100,000, and have raised at least $500,000 in previous funding rounds. They are particularly interested in companies at the seed or Series A stage that have a clear path to the next round of financing.

Moore Venture Partners (MVP) is a San Diego-area venture capital firm founded in 2010 and headquartered in Encinitas, California. The firm backs early, growth, and expansion-stage companies in technology and life sciences, with a particular emphasis on audacious founders building category-defining companies that can positively impact millions of lives. Core sectors include biotechnology, healthcare, and SaaS. Founder and Managing Partner Terry W. Moore brings more than 20 years of experience investing in, founding, leading, and advising technology, clean-tech, and life-sciences companies, and leads a lean team of two investment professionals consistent with the firm's measured investment pace of roughly one new investment per year. MVP has raised multiple fund vintages and is currently deploying its fourth fund, MVP IV, continuing to back life science and technology companies at all stages of growth. Individual check sizes can run up to USD 15 million, though formal fund size and AUM figures are not publicly disclosed. Across 29 disclosed portfolio companies the firm has produced one unicorn and two notable NASDAQ IPOs: Avidity Biosciences (NASDAQ IPO, June 2020, $636 million market cap at IPO), which advances antibody-siRNA complexes combining the modalities of ADCs and nucleic-acid therapeutics; and Savara Pharmaceuticals, which develops inhaled antibiotics for MRSA infection in cystic fibrosis. Portfolio sectors skew toward enterprise applications and life sciences. The most recent disclosed investment was a Series B in UCAP Power in February 2025. Moore Venture Partners takes a patient, high-conviction approach, committing deep operational and strategic support to each portfolio company rather than building a high-velocity fund. The firm's willingness to write checks from seed through late-stage Series C+ gives it the flexibility to follow founders through multiple rounds.

Morado Ventures is a venture capital firm focused on seed-stage investments, partnering with passionate entrepreneurs who tackle complex technological problems using both software and hardware solutions. Their current focus areas include Artificial Intelligence, Data Infrastructure, Industrial Internet, Robotics & Autonomy, Computer Vision, and Health. Founded by Ash Patel and Mike Marquez, Morado Ventures brings extensive experience in leading and investing in technology companies. Ash Patel, a former senior executive at Yahoo!, and Mike Marquez, with a background in corporate development at CBS Interactive and Yahoo!, co-founded the firm to leverage their expertise in identifying and nurturing promising startups. Morado Ventures' investment philosophy emphasizes supporting early-stage, data-fueled companies capable of solving significant challenges in industries ripe for disruption. They actively collaborate with founders to develop and execute successful strategies, providing access to a network of seasoned professionals and resources. Their portfolio includes a diverse range of companies such as Lucid Lane, Tensorfield Agriculture, and Cargomatic, reflecting their commitment to fostering innovation across various sectors.

MoreVC, founded in 2006, is a prominent Israeli venture capital firm specializing in seed and early-stage technology startups. The firm focuses on diverse sectors, partnering with entrepreneurs who are building impactful companies. Notable investments include Vayyar, WeissBeerger, Claroty, and Freightos, showcasing their commitment to innovative and scalable technologies across industries such as cybersecurity, imaging, and logistics​. MoreVC manages several funds, with investments typically ranging from pre-seed to Series A stages. They emphasize strong partnerships with entrepreneurs, providing not just capital but also strategic guidance and a robust network. The firm is known for its founder-friendly approach, often praised for its values and smart advice by portfolio companies. The leadership team, including founding partners Meir Ukeles, Glen Schwaber, and Elliott Sussman, brings extensive experience from various fields such as technology, finance, and public policy. Their combined expertise allows MoreVC to effectively support startups in navigating complex markets and achieving growth.

Morgenthaler Ventures is one of the oldest venture capital and private equity platforms in the United States, founded in 1968 and headquartered in Portola Valley, California, with offices historically in Cleveland, Boulder, South San Francisco, Menlo Park, Massachusetts, and Hawaii. For more than 45 years the firm invested across information technology, life sciences, medical devices, healthcare services, pharmaceuticals, biotechnology, consumer and enterprise software, and mobile computing. Morgenthaler leads rounds. Its Information Technology, Life Sciences, and Private Equity teams together built more than 300 companies and made approximately 526 disclosed investments, producing 101 portfolio exits. Notable IT portfolio companies include Apple (early-stage), Evernote (unicorn), Lending Club (IPO), Siri (acquired by Apple), MuleSoft (acquired by Salesforce), Doximity (IPO, with Morgenthaler's stake valued at approximately $905 million), Practice Fusion, Check, Socrata, NuoDB, Jaspersoft, Voltage Security, and Wize Commerce. Fund IX closed in 2008 at $400 million as a combined IT and life-sciences vehicle. In 2013, IT partners Gary Little, Rebecca Lynn, and Gary Morgenthaler spun out the IT practice into Canvas Venture Fund, which closed at $175 million; the private-equity arm subsequently rebranded as MPE Partners in Cleveland. Morgenthaler Ventures still manages its legacy funds and portfolio under the original banner but no longer raises net-new institutional venture funds. The firm's most recent portfolio exit was FiveStar in November 2024. Across more than five decades the partnership earned a reputation as a generalist investor with the rare ability to back companies from inception through IPO in both technology and life sciences — a duality that few firms have sustained at Morgenthaler's scale and longevity.

Morningside Ventures is the venture capital investing arm of the Morningside Group, a long-standing private-capital platform founded in 1986 by Hong Kong-American brothers Gerald L. Chan, who serves as Chairman of Morningside Ventures, and Ronnie C. Chan, Chairman of Hang Lung Group. Headquartered in Newton, Massachusetts with additional operations in Hong Kong, the firm deploys patient capital across North America, Asia, and Europe with a long-term orientation and an explicit commitment to ethical practice. Life sciences is the dominant concentration, with the team recognized as a pioneer in oncolytic viral therapy, mitochondrial medicine, and innate-immunity modalities spanning toll-like receptors, the STING pathway, the complement cascade, and immune proteasomes. Portfolio companies have received seven FDA Breakthrough Therapy designations and twelve Fast Track designations — a track record few venture firms in any segment can match. The platform has made roughly 431 disclosed investments in aggregate. Average check sizes by stage are approximately $4.5 million at seed (17 deals), $23.9 million at Series A (42 deals), and $49.2 million at Series B (36 deals). Morningside leads rounds. Recent deals include leading a $105 million round in Cognito Therapeutics in March 2026, a $12 million Series B Plus in Accropeutics in March 2025, an $8.5 million pre-Series A in Ampa in October 2025, and an investment in digital health company Xealth in March 2025. The 2025 calendar saw 10 investments in total. Beyond capital, Morningside's philanthropic commitments to the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design reflect the firm's conviction that deep institutional relationships with leading research universities are essential to discovering and backing the next generation of breakthrough science.

Morningstar Ventures is a Dubai-based venture capital firm founded in 2020 by Danilo Carlucci and Arutyun Nazaryan. The firm focuses on investing in blockchain, digital assets, Web3, and decentralized finance (DeFi). With a portfolio spanning 199 investments, Morningstar has backed notable companies such as Unstoppable Domains and Axelar, both of which have achieved unicorn status. The firm typically participates in early-stage funding, ranging from Seed to Series A rounds, with investments averaging between $1 million to $5 million. Morningstar Ventures stands out for its deep involvement in the growth of its portfolio companies, providing not only capital but also strategic support and access to its vast network in the crypto and blockchain industries. In addition to its investment activities, Morningstar operates MSV GG, an initiative that supports Web3 startups by providing them with industry expertise and marketing resources. This holistic approach allows Morningstar to align closely with the companies it invests in, helping them scale rapidly in the competitive blockchain space. With its headquarters in Dubai, the firm has expanded its influence across various regions, focusing on fostering the next generation of decentralized technologies and contributing to the global adoption of blockchain​.